The DOI matches its Crossref record; 338 of the 341 references it cites were found in a registry or an index.
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Open accessAbstract
Singal, Amit G.; Llovet, Josep M.; Yarchoan, Mark; Mehta, Neil; Heimbach, Julie K.; Dawson, Laura A.; Jou, Janice H.; Kulik, Laura M.; Agopian, Vatche G.; Marrero, Jorge A.; Mendiratta-Lala, Mishal; Brown, Daniel B.; Rilling, William S.; Goyal, Lipika; Wei, Alice C.; Taddei, Tamar H. Author Information
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Surgical resection is recognized worldwide as the preferred treatment for patients with early stage HCC, whereas liver transplantation is indicated in those with early stage disease who are not deemed suitable for resection7,22.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In general, European and US guidelines recommend more-restrictive criteria for resection than Asian guidelines7,22–27.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In particular, regimens including immune-checkpoint inhibitors (ICIs) are currently adopted as first-line therapies in clinical guidelines7.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Currently, clinical decisions are based on clinical factors including, but not limited to, performance status, tumour burden, liver function and comorbidities7.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Now the positive results of IMbrave 050 (ref. 12) have led to a revised management algorithm for patients with early stage HCC by incorporating adjuvant therapies in this disease setting7 (Fig. 4).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“[309] mRECIST criteria has been proposed to adapt RECIST criteria to particularities of HCC, enabling capture of antitumoral response without observed shrinkage after local and systemic therapies.”
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationErdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · cited 2×
“…PD-L1, plus bevacizumab, a monoclonal antibody targeting VEGF, as the preferred first-line treatment option for patients with advanced HCC. [312] The median OS of 19.2 months with atezolizumab plus bevacizumab is the longest median OS of any first-line treatment for advanced-stage HCC to…”
InfluentialMazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173 · cited 1×
“[206] 211] The main barrier to LT is a shortage of available liver allografts compared with demand, prompting an allocation system that directs access to deceased donor organs for patients both with and without HCC.”
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationCancer statistics for the year 2020: An overview
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33588 · Cited by 6,308
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832 · cited 1×
“[320] In 2018, lenvatinib (an oral mTKI targeting vascular endothelial growth factor [VEGF]2 and other kinases) met its primary endpoint of noninferiority versus sorafenib in a global phase III randomized study, REFLECT.”
Research works printed but not linked: 2
- Marrero, 2021, GALAD score improves early detection of HCC prior to the diagnosis of HCC: A phase 3 biomarker validation study. Abstract #138, Hepatology, 74, 92A
- Dawson, 2022, ORAL SCIENTIFIC SESSIONS LBA 01: NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937). Int J Radiation Oncol, Biol, Physics, 114, P1057
Cited by
Sorted by citations
Items 701–800 of 1,000
Chen, K. H., Ji, Y., Wang, G., Chen, W., Zhu, Q., Wang, X., Liu, C., & Zhao, X. (2025) · Korean Journal of Radiology · doi:10.3348/kjr.2025.0049 · Cited by 4
“The American Association for the Study of Liver Diseases (AASLD) has recommended MWA as an effective treatment for patients with early HCC ≤3 cm who are ineligible for or refuse surgery [6].”
Causes of mortality among patients with early-stage hepatocellular carcinoma
Dahan, K. S. E., Daher, D., Rich, N. E., Nayak, A., Ankoma-Sey, C., Govalan, R., Bhongade, M. B., Molina, E., Amador, E., Pitts, H., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001471 · Cited by 4
Self-citationZhang, X., Feng, X., Deng, L., Xie, F., Chen, Y., Zhang, J., Yang, X., & Wang, H. (2025) · Liver Cancer · doi:10.1159/000547723 · Cited by 5
Ahn, D. H., Park, N. J., Locker, M., Zhou, Z., Nie, X., Wang, T., & Yu, S. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf252 · Cited by 4
Pushing the limits of treatment for hepatocellular carcinoma
Jones-Pauley, M., Victor, D. W., & Kodali, S. (2023) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001123 · Cited by 4
Tada, T., Kumada, T., Hiraoka, A., Kariyama, K., Yasuda, S., Tada, F., Ohama, H., Nouso, K., Matono, T., Nakamura, S., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16512 · Cited by 4
Peng, W., Pan, Y., Xie, L., Yang, Z., Ye, Z., Chen, J., Wang, J., Hu, D., Xu, L., Zhou, Z., et al. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241237631 · Cited by 5
“9,11,12,14 There is currently a lack of direct head-to-head studies comparing the merits of these first-line treatment strategies.”
BackgroundMohamed, R., Wang, W., Tanwandee, T., Hasan, I., Phạm, C. P., Lim, Y., Lu, S., Munisamy, M., Tran, T. T. H., Ratnawati, E., et al. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01089-5 · Cited by 4
“Comparison of the latest guidelines from the American Association for the Study of Liver Diseases (AASLD) [23], European Association for the Study of the Liver (EASL) [24], and Asian Pacific Association for the Study of the Liver (APASL) [25] reveals a global convergence in HCC treatment strategies…”
Maung, S. T., Tanpowpong, N., Satja, M., Treeprasertsuk, S., & Chaiteerakij, R. (2024) · British Journal of Radiology · doi:10.1093/bjr/tqae140 · Cited by 4
Chai, K. P., Saxena, V., Seo, S., HORTON, B. H., Avins, A. L., Sedki, M., & Ready, J. B. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003116 · Cited by 4
Dai, J., Lai, J. C., Wong, G. L., & Yip, T. C. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0327 · Cited by 4
Outla, Z., Oyman-Eyrilmez, G., Korelova, K., Přechová, M., Frick, L. D., Sarnová, L., Bisht, P., Novotná, P., Kosla, J., Bortel, P., et al. (2024) · eLife · doi:10.7554/elife.102205 · Cited by 4
Clusmann, J., Koop, P., Zhang, D. Y., van Haag, F., Nahhas, O. S. M. E., Seibel, T., Žigutytė, L., Kaewdech, A., Caldéraro, J., Tacke, F., et al. (2024) · medRxiv · doi:10.1101/2024.11.03.24316662 · Cited by 4
A Post-International Gastrointestinal Cancers’ Conference (IGICC) Position Statements
Yalçın, Ş., Laçin, Ş., Kaseb, A. O., Peynırcıoğlu, B., Cantaşdemir, M., Çil, B., Hürmüz, P., Dogrul, A. B., Bozkurt, M., Abalı, H., et al. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s449540 · Cited by 3
“20,21 The imaging criteria for liver nodules is primarily intended for patients at high risk of developing HCC, such as those with liver cirrhosis, chronic hepatitis B, HCV and current or previous history of HCC.”
BackgroundYang, J., Choi, W., Kim, H., Choi, J., Yoo, C., Lee, D., Shim, J. H., Kim, K. M., Lim, Y., & Lee, H. C. (2024) · Liver Cancer · doi:10.1159/000541621 · Cited by 3
“A diagnosis of HCC was established radiologically and pathologically based on international guidelines [20 – 22].”
Li, M., Hannan, L. M., Goyal, L., Bocobo, A. G., Parks, A. L., Bauer, K., Baiev, I., Dinicola, C. F., Gordan, J. D., Venook, A. P., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241297085 · Cited by 3
Self-citationOkushin, K., Tateishi, R., Hirakawa, S., Tachimori, H., Uchino, K., Nakagomi, R., Yamada, T., Nakatsuka, T., Minami, T., Sato, M., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14147 · Cited by 3
“Carnosine-Niosomal Delivery System for Targeted Cancer Therapy”
Atta, A., Salem, M. M., Reda, A., & Mohamed, T. M. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01626-w · Cited by 3
“Late-stage diagnosis can result in a higher burden of disease and decreased survival rates [30].”
Liu, J., Bai, S., Shi, X., Yuan, T., Yu, Y., Lin, J., Dai, C., Wu, Y., Cui, L., Zhu, B., et al. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.109621 · Cited by 3
High prevalence of antinuclear antibodies in hepatitis C related hepatocellular carcinoma
El-Far, M., Mustafa, A. S., Attallah, A. M., & Abdelrazek, M. A. (2025) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2025.2480368 · Cited by 3
“HCC diagnosis was based on American Association for the Study of Liver diseases (AASLD) practice guidelines [13] [ultrasound to detect liver focal lesion(s), AFP ≥ 400 UL −1 , confirmed by computed tomography].”
Wang, Y., Pan, J., Zhao, Q., Dong, G., Ren, Z., Zhang, W., Aji, T., Ji, J., Jiang, T.-A., & Xu, M. (2025) · Academic Radiology · doi:10.1016/j.acra.2025.03.013 · Cited by 3
Parikh, N. D., Park, N. J., Locker, M., Chopra, I., Yeaw, J., & Yu, S. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s496618 · Cited by 3
“8,12,16,17 The incidence of gastrointestinal bleeding events may be higher in real-world settings since the IMbrave150 study required EGD before enrollment and excluded untreated or incompletely treated EGV.”
HCC surveillance in hepatitis C: A longitudinal algorithm improves alpha-fetoprotein screening
Marsh, T. L., Johnston, J. M., Homan, C., Townshend‐Bulson, L., Kim, N. J., VoPham, T., Li, X., He, Q., McMahon, B. J., Ioannou, G. N., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000719 · Cited by 3
“Because every positive screen could lead to further diagnostic testing, we defined the screen-level false-positive rate (FPR, ie, 1-specificity) as the proportion of positive results among all tests conducted among patients without HCC. Screening strategies are often designed with a target FPR to limit the overall bur…”
InfluentialSamuel, A. S., Qiao, A., Merrill, C. D., Ball, C. G., Burrowes, D. P., & Wilson, S. R. (2025) · Abdominal Radiology · doi:10.1007/s00261-025-05046-z · Cited by 3
“Identification of a high-risk population with chronic liver disease requires primary imaging surveillance for de novo masses and secondary surveillance for recurrent disease following therapy [3].”
InfluentialOpportunities to improve surveillance of hepatocellular carcinoma in Australia
Howell, J. A., Emery, J. D., Roberts, S. K., Thompson, A. J. V., Ng, M. K., George, J., Leggett, B., Tse, E., Nguyen, B., Combo, T., et al. (2025) · The Medical Journal of Australia · doi:10.5694/mja2.52691 · Cited by 3
“36 Having accredited radiology services with increased training providing HCC surveillance through a national program may aid in ensuring high quality surveillance.”
Peng, L. (2025) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000093 · Cited by 3
Machine learning improves post-transplantation HCC recurrence prediction
Li, P. J., Ashraf‐Ganjouei, A., Syed, S. M., Mehta, N. J., Alseidi, A., & Adam, M. A. (2025) · Liver Transplantation · doi:10.1097/lvt.0000000000000685 · Cited by 3
Self-citationAmara, D., Melehy, A., Ebaid, S. S., Kaldas, F. M., Farmer, D. G., Stock, P. G., Bui, A. A. T., Mehta, N. J., & Agopian, V. G. (2025) · Clinical Transplantation · doi:10.1111/ctr.70254 · Cited by 3
Self-citationNovel Therapeutics for Hepatocellular Carcinoma
Elsaid, M. I., & Manne, A. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.06.009 · Cited by 3
da Fonseca, L. G., Freire, C. S., Guedes, R. A. V., Lyra, M. C., Braghiroli, M. I., Siqueira, M. B., de Oliveira, M. G., Palladino, A. D. M., Najman, H. L., Tancredi, R., et al. (2025) · JCO Global Oncology · doi:10.1200/go-25-00128 · Cited by 3
Yang, P., Huang, W., Xu, Y., Li, Q., Shu, X., Zuo, J., Ren, W., Huang, Y., Teng, Y., & Shu, P. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003053 · Cited by 3
“…Liver, and the Asian Pacific Association for the Study of the Liver recommend semiannual abdominal ultrasound screening, with or without serum alpha-fetoprotein, for high-risk individuals (including chronic HBV subgroups and patients with liver cirrhosis of any etiology) to monitor for HCC [42–44].”
Hatanaka, T., Shimose, S., Ito, T., Tani, J., Tomonari, T., Saeki, I., Takeuchi, Y., Sasaki, K., Honma, Y., Sasaki, R., et al. (2025) · Hepatology Research · doi:10.1111/hepr.70023 · Cited by 3
“HCC was diagnosed based on pathological findings or characteristic clinical features in accordance with the AASLD guidelines: enhancement during the arterial phase and washout during the portal venous or delayed phases on dynamic computed tomography (CT) or magnetic resonance imaging (MRI) [3].”
Hatanaka, T., Shibuya, K., Kakizaki, S., Hiraoka, A., Tada, T., Kariyama, K., Itobayashi, E., Tsuji, K., Ishikawa, T., Toyoda, H., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000801 · Cited by 3
“…to the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver practice guidelines, [2,3] liver resection is recommended for solitary or localized HCC in patients with cirrhosis with well-preserved liver function and no significant…”
Wei, R., Liu, Z., Ju, L.-L., Zuo, M., Yao, W., Li, W., Fu, Y. H. H., Liu, W., Li, C., Wu, P., et al. (2025) · Radiology Imaging Cancer · doi:10.1148/rycan.250034 · Cited by 3
Liu, J., Zhang, S., & Shao, H. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-099510 · Cited by 3
Park, M.-S., Cho, J. Y., Kim, E., Na, H. Y., Choi, Y., Kim, N. R., Yoon, Y., Lee, B., Jang, E. S., Jung, Y. K., et al. (2025) · Annals of Surgical Treatment and Research · doi:10.4174/astr.2025.109.3.123 · Cited by 3
“The American Association for the Study of Liver Diseases (AASLD) recommends regular imaging and serum α -FP testing every 3–6 months for the first 2 years after surgery to detect recurrence early, which is vital for improving patient outcomes [175].”
Chen, K., Xu, F., Shi, Y., Xiao, H., Xiang, L., & Shi, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1652717 · Cited by 3
“Nevertheless, postoperative recurrence continues to pose a major clinical challenge, signi fi cantly compromising long-term outcomes (37, 38).”
Geometric deep learning adapted to prediction of liver resection zone
Rakshit, J., Kreher, R., Huber, T., Lang, H., Huettl, F., & Saalfeld, S. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111103 · Cited by 3
Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma
Foerster, F., Wiesmann, L., Bark, P., & Galle, P. R. (2025) · Hepatology · doi:10.1097/hep.0000000000001554 · Cited by 3
Rognoni, C., Bhoori, S., Crocetti, L., Mosconi, C., Fonio, P., Bongini, M., Bozzi, E., Brunetto, M., Cappelli, A., Chiesa, C., et al. (2025) · Cardiovascular and Interventional Radiology · doi:10.1007/s00270-025-04214-4 · Cited by 5
“TARE can be used with local control or curative intent, including downstaging [15–17] in an intent-to-re-sect/transplant strategy [7].”
Fakhoury, B., Jahagirdar, V., Alsaqa, M., Sierra, L., Razzak, I. A., Parraga, X., Khalid, M., Bonder, A., Vinayek, R., & Saberi, B. (2025) · Liver Transplantation · doi:10.1097/lvt.0000000000000743 · Cited by 3
Le, T. M., & Pham, K. C. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002257 · Cited by 3
OuYang, L.-Y., Gan, Y., Zhang, C., Jiang, N., Lu, S.-X., Yang, Z., Shi, M., Zhang, Y., Zhou, Z., Chen, M., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101638 · Cited by 6
Hepatocellular carcinoma and liver transplant: What about neo- and adjuvant immunotherapy
Khalaf, M. H., Tran, B. V., Krendl, F. J., Doan, T., Rachko, J., Marino, R., & Tabrizian, P. (2025) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2025.10.004 · Cited by 3
Huang, K., Ho, C.-T., Lee, P., Chen, S., Liu, C., Chou, S., Lee, I., Huang, Y., Luo, J., Hou, M., et al. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001305 · Cited by 3
“5 Comparative studies have extensively evaluated the diagnostic performance of AFP and PIVKA-II in HCC. 23 However, most studies have primarily focused on the diagnostic or surveillance value of these biomarkers and often rely on models that integrate both AFP and PIVKA-II.”
He, Y., Dai, X.-Y., Lv, Y., Yang, X.-J., Xie, Q., Xie, S., Cai, Y., Gao, F., & Lan, T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1670818 · Cited by 3
Meng, X., Chen, F., Tang, T., Xia, T., Qian, Y., Zhao, B., Qu, X., Zhou, Y., Shi, Y., Long, X., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101565 · Cited by 3
Díaz‐González, Á., Molera, C., Domínguez, E. G., Muñoz‐Bartolo, G., Ampuero, J., Fernández‐Rodríguez, C., Quintero, J., Molina, E., Salcedo, M., Olveira, A., et al. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2026.502629 · Cited by 3
Guo, B., Cai, G., Zhu, J., Chen, Q., Li, D., Zhang, H., Liu, Z., Cai, N., Wu, Y., Kuang, D., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.11.054 · Cited by 3
“However, the high rate for recurrence compromised the desired therapeutic state following liver resection (LR) [2].”
InfluentialHu, L., Chen, C., Xiao, Y., Li, Z., Jiang, N., Du, C., Lv, G., Tang, J., & Zeng, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-28296-9 · Cited by 3
“The guidelines from the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) recommend transarterial chemoembolization (TACE) or systemic therapy for patients with BCLC stage B or C 4,5 .”
Akbulut, S., & Çolak, C. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i11.109494 · Cited by 3
Ma, L., Yang, D., Zhong, T.-M., Pang, Q., Luo, M., Li, W., Yan, Y.-H., Chen, K., Wang, G.-D., Yang, F., et al. (2025) · Liver Cancer · doi:10.1159/000549844 · Cited by 3
“…patients who were treated at one of the 23 participating hospitals across China between January 1, 2019, and June 30, 2023, and who (1) were between 18 and 75 years old at baseline, (2) were definitively diagnosed with initially unresectable HCC according to published criteria [24] (online suppl.”
Hu, L., Xu, Y., Qiao, Y., Wang, A., He, C., & Wang, R. (2025) · BMC Cancer · doi:10.1186/s12885-025-15449-2 · Cited by 3
“…by the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD), individuals with Barcelona Clinic Liver Cancer (BCLC) grade B or C are recommended to undergo transarterial chemoembolization (TACE) or systemic therapy [4, 5].”
Risk Scores for Stratifying Hepatocellular Carcinoma and Optimizing Surveillance Strategies
Chang, Y.-P., Chen, Y.-C., & Liu, C. (2026) · Cancers · doi:10.3390/cancers18010158 · Cited by 3
“Hepatocellular carcinoma (HCC) is the most common type of liver cancer, which accounts for approximately 75–86% of all cases [2].”
InfluentialPark, H. J., Choi, J., Kim, D. W., Choi, S. H., Choi, W., Chung, S. W., Lee, D., Shim, J. H., Lee, H. C., Lim, Y.-J., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000839 · Cited by 3
Self-citationAl‐Khreisat, M. J., Abosaoda, M. K., Ibrahim, N. A., Malathi.H, M., Priyadarshini‐Nayak, P., Sathiya‐Priya, V., Singh, G., & Chauhan, A. S. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70197 · Cited by 3
“Therefore, combining CTC analysis with conventional markers like AFP could improve overall detection accuracy in HCC [125, 126].”
Pinjaroen, N., Ngum, W. P., Poovorawan, K., Wastlund, D., Mueller, F., Lu, P., Yu, R. S. S., & Tangkijvanich, P. (2026) · PLoS ONE · doi:10.1371/journal.pone.0337913 · Cited by 3
“Current professional recommendations for HCC surveillance, including the Thailand HCC guideline, suggest screening using ultrasound (US) coupled with serum alpha-fetoprotein (AFP) every 6 months in patients with cirrhosis [2,7].”
Yeo, Y. H., Ho, H. J., Huang, T., Lee, T., Yang, J. D., Cholankeril, G. T., Chen, C., Yang, H.-I., Chen, C., Chang, H.-C., et al. (2026) · Liver Cancer · doi:10.1159/000550360 · Cited by 3
“…guidelines, such as the AASLD, have advocated surveillance at higher thresholds (e.g., 1.5% annually) based on older analyses published before 1996 [34], a recent landmark article demonstrated that biannual ultrasound surveillance combined with alpha-fetoprotein (AFP) testing is cost-effective…”
InfluentialWang, G., Chen, W., Liang, Z., Ding, F., Cui, J., Shen, Z., Lin, F., Li, X., Wang, X., & Zhao, X. (2026) · Communications Biology · doi:10.1038/s42003-026-09571-5 · Cited by 3
“Accurate prediction of postoperative recurrence can affect the selection of treatment options and surveillance strategies 5 .”
Cao, J., Zhu, T., Sun, Q., Liu, Y., Yu, H., Guo, X., Liu, Q., Ding, X., Wang, J., Wu, Z., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1764150 · Cited by 3
Niriella, M. A., Dayananda, P. M., Ranathunga, V. S., Wijesingha, I. P., de Silva, T., & de Silva, H. J. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01401-5 · Cited by 3
“Local ablative therapy, either chemical or thermal, can be used as an alternative to surgery in the early stages of BCLC cases with preserved liver function, even in the presence of portal hypertension [53, 54].”
InfluentialTaiwan Academy of Tumor Ablation (TATA) consensus on hepatocellular carcinoma ablation
Chang, C.-H., Wu, M. S., Kao, W., Chiang, M.-F., Hsu, S., Wang, S.-Y., Hung, C., Wu, C. H., Chen, S., Cheng, Y.-M., et al. (2026) · Hepatology International · doi:10.1007/s12072-026-11050-2 · Cited by 3
Alawi, M., Raahim, M., Kumar, M., Chin, K. K., Aramwit, P., & Mahmood, S. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s573137 · Cited by 5
Fazlollahi, F., Carfora, A. D., King, M., Wrasman, E. S., & Makary, M. S. (2026) · Current Oncology · doi:10.3390/curroncol33030172 · Cited by 3
Zheng, C., Araque, M., Quiej, A., Buchanan-Peart, K.-A., & Jones, P. D. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01428-8 · Cited by 3
“…for HCC, including cirrhosis and chronic HBV, should undergo semiannual screening with ultrasound ± alpha-fetoprotein, per the American Association for the Study of Liver Diseases (AASLD) [ 41 ] guidance and the European Association for the Study of the Liver [ 42 ] clinical practical guidelines.”
Implementation science: a primer for hepatology research
Verma, M., Tahir, H., & Kalman, R. S. (2026) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001164 · Cited by 3
Yan, J., Wang, J., Jian, F., Cui, X., Zhang, Y., Yang, X., Gao, Q., Ding, Z., 汤钊猷, Fan, J., et al. (2026) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70033 · Cited by 3
Ding, R., Bai, J., Jin, Z., Xiao, Y., Chen, J., Zhu, X.-L., Xin, Y., Chen, J., Tie, J., Zhu, K.-S., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70612 · Cited by 3
Hepatocellular Carcinoma Bridging and Downstaging: Advances in Locoregional Therapy
Fite, E. L., Sekar, N., Venancius, J., & Makary, M. S. (2026) · Biomedicines · doi:10.3390/biomedicines14040877 · Cited by 3
“Many preliminary trials have looked at a combination approach between systemic therapy and LRT, but this method is not currently recommended as a treatment modality [5].”
InfluentialCirculating Methylated SEPT9 for Detection of Hepatocellular Carcinoma in Cirrhosis
Oussalah, A., Rodriguez, M. S., Conroy, G., Bensenane, M., Rousseau, H., Ayav, A., Guéant, J., Camara, H., Baumann, C., Laurent, V., et al. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2026.2157 · Cited by 3
Surveillance of patients at risk of liver cancer: Expert opinions
Yip, T. C., Innes, H. A., Wong, G. L., & Jepsen, P. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.03.017 · Cited by 3
Lin, S. H., Wu, J., Tsai, Y., Tseng, C., Chen, P., & Hsu, Y. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70555 · Cited by 3
“In routine practice, clinicians may preferentially select Durva/Treme for patients perceived to have higher bleeding risk, and international guidance similarly recommends Durva/Treme over Atezo/Bev for patients with a high risk of GI bleeding [10].”
Furlan, A., Dasyam, N., Buros, C. M., Thompson, C. P., Minervini, M. I., & Kierans, A. S. (2023) · Current Problems in Diagnostic Radiology · doi:10.1067/j.cpradiol.2023.12.001 · Cited by 3
Gerum, S., Grambozov, B., & Roeder, F. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-771 · Cited by 3
Abbreviated magnetic resonance imaging in hepatocellular carcinoma surveillance: A review
Ramegowda, R., & Gupta, P. C. (2024) · Indian Journal of Gastroenterology · doi:10.1007/s12664-023-01511-z · Cited by 3
Hu, Q., Tian, Z., Sun, Y., Zhang, B., & Tang, Z. (2024) · International Journal of Hyperthermia · doi:10.1080/02656736.2024.2306818 · Cited by 3
“The diagnosis of HCC was based on the typical imaging appearance of contrast enhanced computed tomography (CECT) or magnetic resonance imaging (CEMRI) combined with clinical findings according to AASLD [24, 25].”
Song, B. G., Goh, M. J., Kang, W., Sinn, D. H., Gwak, G., Paik, Y., Lee, J. H., & Choi, M. S. (2024) · Journal of Liver Cancer · doi:10.17998/jlc.2024.05.26 · Cited by 3
Wen, R., Peng, Y., Liang, Y., Wu, Y., Li, H., Chen, Y., Qin, Y., Wen, Z., Cui, H., He, Y., et al. (2024) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2024.08.003 · Cited by 3
Charbonneau, J., Couture, T., Turgeon, A. F., O'Connor, S. E., Ouellet, J.-F. B., Ouellet, J.-F. B., & Brind’Amour, A. (2024) · HPB · doi:10.1016/j.hpb.2024.08.008 · Cited by 3
Takeda, Y., Imamura, H., Sano, K., Ichida, H., Yoshioka, R., Mise, Y., Matsuyama, Y., & Saiura, A. (2025) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2025.101989 · Cited by 3
Yuan, T., Liu, J., Lv, X., Zhang, E., & Huang, Z. (2025) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000085 · Cited by 3
Proton beam therapy in the management of hepatocellular carcinoma
Chok, K., Joeng, T. Y., & Poon, D. M. C. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2495080 · Cited by 3
Liou, W. L., Tan, S., Yamada, H., Krishnamoorthy, T. L., Chang, J. P.-E., Yeo, C., & Tan, C. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16997 · Cited by 3
Lee, J., Yang, K., Han, J. W., Sung, P. S., Jang, J. W., Yoon, S. K., Cho, H. S., Yang, H., Bae, S. H., Kim, J. H., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0495 · Cited by 3
“To address these issues, this study aims to compare the treatment outcomes among patients with CPS 5, 6, and 7.”
Zhao, Y., Bai, W., Ding, R., You, N., Zheng, L., Li, L., Wu, J., Zhang, P., Huang, W., Zhang, H., et al. (2025) · Liver Cancer · doi:10.1159/000546530 · Cited by 4
Abbreviated MRI-Based Surveillance Strategies for Early Hepatocellular Carcinoma Detection
Park, H. J., Kim, D. W., Choi, W., & Kim, S. Y. (2025) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2024.0153 · Cited by 3
Second-line antidiabetic drugs: friend or foe of the liver
Yang, J., Kim, G., Shim, J. H., & An, J. (2025) · Journal of Liver Cancer · doi:10.17998/jlc.2025.06.25 · Cited by 3
Liang, Z., Jin, L., Li, H., Dai, H., Zhang, Y., Wang, F., Ma, W., Yu, H., Chen, X., Kong, Q., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-13406-4 · Cited by 3
“The 2023 AASLD guidelines 26 recommend concurrent antiviral therapy during anticancer treatment for HCC patients.”
Wen, X., Xu, Z., Wang, H., Wang, Y., Gu, Q., Jiang, X., Chen, C., & Yu, Y. (2025) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2025.110513 · Cited by 3
Maesaka, K., Hikita, H., Kai, M., Tahata, Y., Shirai, K., Doi, A., Murai, K., Saito, Y., Yamada, R., Kodama, T., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70068 · Cited by 3
Advances in the Diagnosis, Treatment, and Management of Liver Nodules: A Comprehensive Review
Gao, C. J., Chen, D., & Chen, Y. (2025) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70020 · Cited by 3
Li, J., Yang, D.-L., Wang, J., Tian, W., Wei, W., Luo, C., Qi, L., Ma, L., & Zhong, J. (2023) · Journal of Surgical Case Reports · doi:10.1093/jscr/rjad610 · Cited by 3
Sonthalia, N., Roy, A., Jajodia, S., Goenka, U., Sutradhar, A., Tewari, A., & Goenka, M. K. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2023.101307 · Cited by 3
Tavabie, O. D., Salehi, S., & Aluvihare, V. R. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2292642 · Cited by 3
“However, the American Association for the Study of Liver Disease have recommended against routine surveillance of patients without cirrhosis who have hepatitis C post cure or nonalcoholic fatty liver disease [63].”
BackgroundBui, H. T., Kumar, N. G., Singal, A. G., Boparai, J., Mukhtar, N. A., Tran, D. K., Saxena, V., & Balasubramanian, S. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002704 · Cited by 3
“Given this presumed bene fi t of early HCC detection, professional societies such as the American Association for the Study of Liver Diseases (AASLD) and American Association for the Study of Liver Diseases (AASLD)recommend HCC surveillancein at-risk patients, including those with cirrhosis (4,5).”
Self-citationMonitoring for liver cancer post‐gene therapy—How much and how often?
de Jong, Y. P., & Jacobson, I. M. (2024) · Journal of Viral Hepatitis · doi:10.1111/jvh.13898 · Cited by 3
Novel biomarkers and strategies for HCC diagnosis and care
Wang, A. E., Leven, E. A., Grinspan, L. T., & Villanueva, A. (2024) · Clinical Liver Disease · doi:10.1097/cld.0000000000000152 · Cited by 3
Allaire, M., Sultanik, P., & Thabut, D. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101120 · Cited by 3
Flamm, S. L. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.05.015 · Cited by 5
Zhang, L., Yang, H., Ning, S., Wu, Z., Wang, D., Liang, H., Wang, C., & Xu, C. (2024) · Cancer Medicine · doi:10.1002/cam4.7410 · Cited by 3
Metadata
- Authors
- Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., Mendiratta-Lala, M., Brown, D. B., Rilling, W. S., Goyal, L., Wei, A. C., & Taddei, T. H.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Johns Hopkins University (US)
- University of California, San Francisco (US)
- Mayo Clinic (US)
- University Health Network (CA)
- Oregon Health & Science University (US)
- Northwestern Medical Faculty Foundation (US)
- University of California, Los Angeles (US)
- University of Pennsylvania (US)
- Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
- Vanderbilt University Medical Center (US)
- Medical College of Wisconsin (US)
- Stanford Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- Yale University (US)
- Corresponding author
- Singal, Amit G.
- ORCID
- Venue
- Hepatology
- Published
- 2023-05-22
- Volume
- 78
- Issue
- 6
- Pages
- 1922-1965
- ISSN
- 0270-9139 (ISSN-L)
- PMC
- PMC10663390
- OpenAlex
- W4377011124
- Cited by
- 2,052
- References
- 341
- Citations by year
- 2026: 760 · 2025: 724 · 2024: 467 · 2023: 97
- FWCI
- 346.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- American Association for the Study of Liver Diseases
- Gilead Sciences
- Boston Scientific Corporation
- Exelixis
- Incyte
- Cancer Research UK (26813)
- Eisai
- Ipsen
- Sirtex Medical
- National Institutes of Health (UL1TR001863)
- Genentech
- National Cancer Institute (P50CA062924, R01CA285544)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Keywords
- hepatocellular carcinoma, hepatocellular carcinoma prevention, hepatocellular carcinoma diagnosis, hepatocellular carcinoma treatment, liver cancer, clinical guidelines
- MeSH terms
- Contrast Media, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Tomography, X-Ray Computed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
